Netherlands' Argenx Q2 net sales rise
Netherlands' Argenx Q2 net sales rise
Overview
Netherlands immunology firm's Q2 product net sales rose 60% yr/yr and 17% sequentially
Q2 net profit and EPS more than doubled from prior year
Growth driven by expanded VYVGART label to all gMG serotypes
Outlook
Company expects topline results from myositis study in 3Q26 and MMN study in 4Q26
argenx plans to launch VYVGART SC autoinjector for all approved indications in 2027
Company expects to have ten molecules in clinical development by end of 2026
Result Drivers
VYVGART LABEL EXPANSION - Q2 growth driven by launch of expanded VYVGART and VYVGART Hytrulo label to all gMG serotypes, broadening patient reach
COMMERCIALIZATION INVESTMENT - Increased selling, general and administrative expenses mainly due to global commercialization of VYVGART franchise and personnel costs
PIPELINE DEVELOPMENT - Higher research and development expenses attributed to advancing efgartigimod, empasiprubart, and adimanebart across multiple registrational studies and early-stage programs
Company press release: ID:nGNE4NPWD3
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| $7.32 |
|
Q2 Net Income |
| $472 mln |
|
Q2 Basic EPS |
| $7.58 |
|
Q2 Operating Expenses |
| -$1.05 bln |
|
Q2 Total Operating Income |
| $1.54 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for argenx SE is €900.00, about 18.7% above its July 22 closing price of €758.40
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 25 three months ago
Reuters Recommended Reads
July 22 - Sweden's Hansa Biopharma Q2 revenue dips
July 21 - Novartis backs full year forecast after $6 billion profit beat helped by one-offs
July 20 - Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)